TGFB1 and idiopathic pulmonary fibrosis: Prior to Omipalisib, Everolimus, a selective mTORc1 inhibitor, was tested in 89 IPF patients but worsened disease progression, possibly due to its partial inhibition of 4E-BP1, a key driver of TGFβ1-induced collagen production (67, 68).